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Background:We investigated the value of plasma deoxyribonucleic acid concentrations in patients presenting
with acute abdominal pain to predict need for intensive care or mortality.
Methods: Plasma deoxyribonucleic acid taken from patients with acute abdominal pain was analyzed for the
β-globin gene using the quantitative polymerase chain reaction. The primary outcome measure was the
combined 28-day mortality or admission to the intensive care unit.
Results: Of 287 consecutive patients with acute abdominal pain recruited, 12 patients were admitted to the
intensive care unit and/or died. Median plasma DNA concentrations were higher in patients with cancer and
major organ inﬂammation. Mean plasma DNA concentrationswere three-fold higher in patients with systemic
inﬂammatory response syndrome, ﬁve-fold higher in patients who died within 28 days, and eight-fold higher
in patients admitted to the intensive care unit. The area under the receiver operator curve for plasma DNA
concentrations and intensive care unit admission/mortality was 0.804. At a cut-off of 1100 GE/ml, the
sensitivity was 67% (95%CI 35–90) and speciﬁcity was 89% (95%CI 84–92). At a cut-off of 175 GE/ml, the
sensitivity was 100% (95%CI 73–100) and speciﬁcity was 30% (95%CI 25–36). Plasma DNA concentration
predicted need for intensive care unit admission or death (adjusted odds ratio 1.4; Pb0.0001).
Conclusions: Plasma DNAmay have a role in patients with acute abdominal pain as a marker for inﬂammation
and cancer, and a predictor of intensive care unit admission/mortality.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Acute abdominal pain is a common presenting complaint encoun-
tered in emergency departments throughout the world [1–3] and is
associated with potentially life-threatening pathology [4]. The
challenge for frontline clinicians is primarily to safely and efﬁciently
differentiate benign from life-threatening causes, and to make
appropriate decisions regarding admission to hospital, to intensive
care or for emergency surgery.
Strategies to improve the early diagnostic accuracy and risk-
stratiﬁcation of patients presenting with acute abdominal pain have
included clinical scoring methods [5,6], blood and urinary markers
[7,8], ultrasound and CT imaging [5,9–14] and minimally-invasive
surgery [15]. The complexity of presentation of acute abdominal pain
has not produced a simple score that is clinically useful. There is a
need to identify clinical predictors or other markers of potential life-
threatening acute abdominal pain.
Circulating nucleic acids are becoming increasingly important as
diagnostic and prognostic tools in prenatal diagnosis [16–21], cancer
[22–26], graft rejection [27], trauma [28,29], stroke [30–32] and acute
coronary syndrome [33,34]. Although the mechanisms by which
nucleic acids are released into the circulation are unknown, it is likely
that cell death is one major factor [35,36]. The good correlation
between the circulating DNA level and the severity of trauma or the
presence of organ failure suggests that DNA is rapidly released into the
circulation when there is a massive tissue destruction [29].
We hypothesized that the concentration of plasma DNA in patients
suffering from acute abdominal pain would be signiﬁcantly higher in
patients with life-threatening causes of abdominal pain involving
inﬂammation and tissue destruction than in patients suffering from
less serious diseases. We determined whether plasma DNA concen-
trations taken from patients presenting with acute abdominal pain
predict mortality and need for intensive care.
2. Materials and methods
Approval was obtained from the Institutional Review Board of the Chinese
University of Hong Kong to conduct a prospective study investigating the role of
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plasma DNA analysis in patients presenting with acute abdominal pain to the Prince of
Wales Hospital.
2.1. Subjects, sample collection and follow-up
Eligible patients aged ≥15 y presenting to the emergency department with acute
abdominal pain were recruited consecutively into the study. Exclusion criteria included
external blunt or penetrating trauma (due to an external force associated with a motor
vehicle crash, fall or assault etc.), known non-surgical causes for abdominal pain (for
example, diabetic ketoacidosis, urinary tract infection, gastro-esophageal reﬂux, or
indigestion (dyspepsia)), and patients unable to give consent. Informed, written
consent was obtained either from the patient or a relative in all cases. Forty healthy
control subjects were recruited which were matched with the 287 patients for age
(mean±SD 46.4 y±16.4 vs. 50.8 y±20.0; unpaired t test P=0.20) and sex (male to female
ratio 24:46 vs. 154:133; Fisher's exact test P=0.50). Control subjects included staff or
their relatives with no history of recent acute illness within 3 months, chronic illness,
smoking or medication.
2.2. Data collection, deﬁnitions and diagnostic imaging
Acute abdominal pain was deﬁned as pain occurring within 7 days of onset and in
an area extending below the lower ribs, above the inguinal line and between the mid-
axillary lines. Data collected included age, sex, symptom onset time, history of previous
abdominal pain, seizures, hypertension, diabetes mellitus, ischemic heart disease, atrial
ﬁbrillation, hyperlipidemia, smoking, antithrombotic and other medication.
In order to determine the exact nature and cause of the acute abdominal pain,
patients received a standard clinical, laboratory and imaging workup. The patients were
managed by emergency physicians according to standard practice and without any
information about the plasma DNA results.
For patients requiring admission, their clinical information including the deﬁnitive
diagnosis and pathological results of resected specimens were reviewed after discharge.
All specimens were reviewed by a Specialist Pathologist whowas blinded to the plasma
DNA. Patients not requiring admission were contacted by telephone two week after the
initial consultation to review whether they needed further consultation, admission or
surgical intervention.
A ﬁnal diagnosis was determined either by a specialist surgeon if the patient was
admitted, or by an emergency medicine specialist if the patient was discharged directly
from the emergency department. Clinicians were blinded to the plasma DNA level
results at the time of diagnosis. Patient diagnostic groups for analysis were determined
by the authors. Severe inﬂammatory response syndrome (SIRS) is said to occur if there
are two or more of the following: temperature N38 °C or b36 °C; tachycardia N90 beats/
min; respiratory rate N20 breaths/min or carbon dioxide and partial pressure (PCO2)
b4.3 kPa; white blood cell count N12×109/l or b4×109/l or N10% immature (band) forms
[37]. Infection and sepsis are deﬁned according to standard guidelines [37].
2.3. Sample collection, processing of plasma and DNA extraction
A 5 to 10ml blood sample was withdrawn from the antecubital vein of each patient,
collected into tubes containing EDTA, centrifuged at 1600 g for 10 min, and plasma was
then transferred into plain polypropylene tubes for a further centrifugation at 16,000 g
for 10 min, and stored at −80 °C pending further processing. DNA was extracted from
0.8 ml of plasma using the QIAamp Blood MiniKit (Qiagen, Hilden, Germany) following
manufacturer's recommendations [38]. An elution volume of 50 µl was used.
2.4. Real-time quantitative PCR
Plasma DNA was measured using a real-time quantitative PCR assay targeting the
β-globin gene as previously described [28]. Real-time PCR analysis was performed
using an Applied Biosystems PRISM 7700 Sequence Detector (Applied Biosystems, CA).
Standard curves were established by serial dilutions of known amounts of DNA
extracted from human buffy coat. Five microliters of extracted plasma DNAwas used for
each ampliﬁcation. Each real-time quantitative PCR assay was performed on an optical
96-well PCR reaction plate. In the present study, therewere 287 patients and 40 healthy
samples. Every sample was analyzed in duplicate. Serial dilutions of the standard curve
included were included in each assay (batch). Ten assays (a batch) were carried out on
10 different plates. In order to ensure the consistency of all the assays, 2 different known
amounts of plasma DNA samples were included in every assay. The precision of the real-
time quantitative PCR assay has been reported previously (18), with a CV for the
threshold cycle of 1.1%. Raw data were subsequently converted into units of copies of
genomes per ml plasma. DNA levels are given to the nearest 25 genome-equivalents
(GE)/ml. The detection limit of the real-time PCR was 1 GE per reaction (equivalent to
12.5 GE/ml plasma). Four negative controls were included in every assay. Negative
controls are “no template controls” i.e. a complete reaction mix without plasma DNA
samples. No DNA should be ampliﬁed and detected after the assay is completed,
otherwise the assay is said to be contaminated.
Table 1
Characteristics of the 287 patients presenting to hospital with acute abdominal paina
Characteristics Value
Age (y) 51 [33–70]
Age N65 y 88 (31%)
Male sex — no. of patients (%) 133 (40%)
Previous history of chronic illnessb 97 (34%)
Time from onset of abdominal pain to blood sample (h) 48 [48–120]
Onset b24 h 71 (25%)
Onset N24 h 216 (75%)
Admitted to hospital — no. of patients (%) 249 (87%)
Urgent operation — no. of patients (%) 65 (23%)
Diagnosis at discharge — no. of patients (%)
Non-speciﬁc abdominal pain of low signiﬁcancec 148 (52%)
Cancer 17 (6%)
Carcinoma of colon 8
Carcinoma of pancreas 4
Hepatocellular and renal cell carcinoma 2
Obstetric and Gynecological 15 (5%)
Acute pelvic inﬂammatory disease 9
Ovarian cyst 6
Organ inﬂammation 79 (27%)
Acute cholangitis/cholecystitis 28
Acute appendicitis 22
Acute diverticulitis 7
Acute peptic ulceration 7
Acute pancreatitis 7
Abscess/peritonitis/ischemic bowel/peritonitis 8
Organ obstruction 28 (10%)
Intestinal obstruction 20
Urolithiasis 8
a All continuous data are expressed as medians [interquartile range]. Numbers may
not sum to 100 because of rounding, multiple factors (for example risk factors) or absent
data. Categorical variables are presented as values (percentages).
b Chronic illness includes previously diagnosed hypertension (n=35), diabetes
mellitus (n=30), ischemic heart disease (n=16), congestive heart failure (n=5), atrial
ﬁbrillation (n=6), hyperlipidemia (n=9), stroke (n=15), chronic obstructive airways
disease (n=9), cancer (n=21) and psychiatric illness (n=2).
c Includes non-speciﬁc undiagnosed abdominal pain, gastroenteritis, simple hernias,
hepatic cirrhosis, herpes zoster, and mesenteric adenitis.
Table 2
Univariate comparison of plasma DNA concentrations and outcome variables (n=287)a
Outcome variable No Yes “x” fold
increase
Mean difference P valueb
N DNA concentration N DNA concentration
Hospital admission 38 225 249 950 4 725 (50 to 1400) 0.0343
Operation required within 28 days 206 700 81 1300 2 600 (100 to 1100) 0.0194
Readmission to hospital 226 575 61 1930 3 1350 (800 to 1875) b0.0001
SIRSc 228 625 56 1825 3 1200 (625 to 1750) b0.0001
Infection 239 725 48 1550 2 825 (200 to 1425) 0.0083
Sepsis 263 750 21 2300 3 1525 (675 to 2400) 0.0006
ICU admission alone 282 775 5 6000 8 5250 (3600 to 6875) b0.0001
Mortality alone 278 725 9 3450 5 2650 (1375 to 3950) b0.0001
ICU admission and/or mortality 275 700 12 4725 7 4025 (2975 to 5075) b0.0001
a Values are rounded off to the nearest 25 GE/ml and shown as means and the mean difference (95% conﬁdence intervals).
b Unpaired student t test is used for comparing means.
c SIRS, systemic inﬂammatory response syndrome.
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2.5. Outcome
The primary outcome measure was the composite 28-day mortality or ICU
admission. Secondary outcome measures were readmission and SIRS.
2.6. Statistical analysis
Descriptive statistics and data comparison tests – chi-square, Fisher's exact, Mann–
Whitney and Kruskal–Wallis tests – were carried out using Statview® for Windows
version 5.0 Statistical Analysis Software (Abacus Concepts, SAS Institute, Cary NC).
Medcalc (Mariakerke, Belgium) was used for ROC analysis. The Bonferroni–Dunn test
was used for multiple comparisons (i.e. when more than two groups were analysed), in
order to reduce the probability that statistical signiﬁcance arose from multiple testing
rather real differences. The Kruskal–Wallis test was used because the number of cases in
some groups (e.g. ICU and mortality) is small.
Multiple logistic regression analysis was used to determine the independent
contribution of multiple variables to the outcome. Variables were initially entered into
the model based on prior clinical reasoning rather than statistical signiﬁcance (i.e., age,
gender, plasma DNA, positive CT ﬁnding, positive US ﬁnding, chronic illness, time from
symptoms onset to sampling, pulse rate N90 beats/min, temperature N38 °C, respiratory
rate N20 breaths per minute, leukocyte count N12×109/L, Alvarado score, amylase N100
and need for operation). Later statistically insigniﬁcant variables (PN0.05) were
removed stepwise until only signiﬁcant independent variables remained.
3. Results
Characteristics of the 287 adult patients who presented with acute
abdominal pain possibly requiring surgical intervention during the
period of recruitment are shown in Table 1. Differences in median
plasma DNA concentrations between the ﬁve clinical groups — cancer
(500 GE/ml), obstetric/gynecological (250 GE/ml), inﬂammatory
(675 GE/ml), obstructive (325 GE/ml), and non-speciﬁc abdominal
pain (225 GE/ml) are statistically signiﬁcant (Pb0.0001; Kruskal–
Wallis test). Six patients had gastrointestinal hemorrhage associated
with abdominal pain (2 patients had Mallory–Weiss Syndrome and 4
patients had melena). Compared with those patients with non-
speciﬁc abdominal pain or benign conditions mean plasma DNA levels
were signiﬁcantly elevated in patients with cancer (500 vs. 250 GE/ml;
Pb0.0167; Bonferroni–Dunn test) and acute abdominal inﬂammation
(650 vs. 250 GE/ml; Pb0.0167; Bonferroni–Dunn test).
Mean plasma DNA concentrations and primary and secondary
outcomes are shown in Table 2. Mean plasma DNA concentrations
were four-fold higher in patients who were admitted to hospital,
three-fold higher in patients with SIRS, ﬁve-fold higher in patients
who diedwithin 28 days, and eight-fold higher in patients admitted to
the ICU. Plasma DNA concentrations correlated with SIRS score
(Pb0.0001; Kruskal–Wallis test; Pb0.005 between SIRS scores 0 and
3, 1 and 2, and 1 and 3; Bonferroni–Dunn test).
Fig. 1 shows the signiﬁcant increase in median plasma DNA
concentrations between healthy control subjects, patients immedi-
ately discharged, patients admitted, patients requiring operation, and
patients admitted to ICU and/or who died (Pb0.0001; Kruskal–Wallis
test).
Fig. 2 shows the receiver operator curve for plasma DNA
concentrations and ICU admission/mortality (area under the curve is
0.804; 95% CI 0.753 to 0.848). At a cut-off of 1100 GE/ml, the sensitivity
is 67% (95%CI 35–90) and speciﬁcity is 89% (95%CI 84–92). At a cut-off
of 175 GE/ml, the sensitivity is 100% (95%CI 73–100) and speciﬁcity is
30% (95%CI 25–36). At a cut-off of 2150 GE/ml, the sensitivity is 58%
(95%CI 28–85) and the speciﬁcity is 95% (95%CI 92–97).
Table 3 shows the adjusted odds ratios for predicting ICU
admission or mortality. When all variables were entered into the
model, only the presence of positive ﬁndings at CT and plasma DNA
concentration predicted need for ICU admission or death.
Fig. 1. Plasma DNA concentrations in patient groups and healthy controls. Plasma DNA
concentrations as determined by real-time quantitative PCR targeting the β-globin gene
(y-axis). Groups are shown on the x-axis and include healthy control subjects (0),
patients immediately discharged (1), patients admitted (2), patients requiring operation
(3), and patients admitted to ICU and/or who died (4). Therewere signiﬁcant differences
across the groups (Kruskall–Wallis test Pb0.001) and between groups 0 to 3 and group
4 (Bonferonni–Dunn Pb0.055). The lines inside the boxes denote medians whilst the
boxes mark the interval between the 25th and 75th percentiles. The whiskers denote
the interval between the 10th and 90th percentiles.
Fig. 2. Receiver operator curve for plasma DNA concentrations and ICU admission/
mortality. This ﬁgure shows the receiver operator curve for plasma DNA concentrations
and ICU admission/mortality (area under the curve is 0.804; 95% CI 0.753 to 0.848). At a
cut-off of 1100 GE/ml, the sensitivity is 67% (95%CI 35–90) and speciﬁcity is 89% (95%CI
84–92). At a cut-off of 175 GE/ml, the sensitivity is 100% (95%CI 73–100) and speciﬁcity
is 30% (95%CI 25–36). At a cut-off of 2150 GE/ml, the sensitivity is 58% (95%CI 28–85)
and the speciﬁcity is 95% (95%CI 92–97).
Table 3
Adjusted odds ratios for predicting ICU admission or mortality (n=287)a
Factor Adjusted odds ratio 95% CI P value
Positive CT ﬁndings 4.5 1.1–17.8 0.0346
Reference — negative CT ﬁndings –
Plasma DNA per 1000 GE/mlb 1.4 1.2–1.6 b0.0001
a Initial independent variables entered into the model included age, gender, plasma
DNA, positive CT ﬁnding, positive US ﬁnding, chronic illness, time from symptoms onset
to sampling, pulse rate N90 beats/min, temperature N38 °C, respiratory rate N20 breaths
per minute, leukocyte count N12×109/L, Alvarado score, amylase N100 and need for
operation. The dependent variable was need for ICU admission or death within 28 days.
Insigniﬁcant independent variables were removed from the model stepwise until only
those variables with P valueb0.05 remained.
b The odds of ICU admission or death increased 40% for every 350 GE/ml increase in
plasma DNA.
115T.H. Rainer et al. / Clinica Chimica Acta 398 (2008) 113–117
4. Discussion
This study shows that circulating plasma DNA concentrations,
assessed by measuring β-globin gene concentrations using real-time
PCR, are increased in patients presenting to an emergency department
with acute abdominal pain requiring admission, are highest in
patients with major inﬂammatory diseases and cancer, and correlate
with increasing severity of systemic inﬂammation. Plasma DNA is
clearly a non-speciﬁc rather than a speciﬁc diagnostic marker which
may be useful for determining need for admission to hospital, need for
intensive care, and for 28-day mortality risk.
In this study we hypothesized that as plasma DNA is likely to be
released from damaged, inﬂamed and necrotic tissues, and that in the
appropriate clinical context e.g. acute abdominal pain, it might act as a
marker for serious intra-abdominal pathology. We have demonstrated
a role for plasma DNA analysis in identifying the presence of
potentially life-threatening conditions for patients presenting with
acute abdominal pain, for example patients with high SIRS scores,
inﬂamed organs, and intra-abdominal cancer. The test is insensitive in
detecting other conditions.
The relative lack of sensitivity of this test in picking up certain
pathologic conditionsmayﬁrstly be related to the relatively small amount
of the affected tissues. Plasma DNA is a non-speciﬁc marker that may be
released from any nucleated cell. Quantities of DNA released from other
tissues into plasma may be greater than that released from an inﬂamed
appendix. Some of the highest levels of plasma DNA are seen in patients
withmultiple trauma inwhich there is a large amount of damaged tissue
[27]. In patients with acute stroke with catastrophic clinical effects, the
amount of damaged neurological tissue may be quite small.
Elderly patients have elevated circulatingplasmaDNA levelswhich is
most pronounced in those with chronic illness [35]. Similar to other
studies in an emergency department setting, plasma DNA levels may
give a general indication of the health of a patient presenting as a
potential emergency. Moderate increases in plasma DNA may not
necessarily indicate an acute event but may be associated with the
chronic inﬂammatory and atherosclerotic processes which are often
associated with aging. In our study chronic illness was associated with
increased plasmaDNAconcentrations butwhen entered into the logistic
regression model for ICU admission/mortality the adjusted odds ratio
was not signiﬁcant. Therefore in our study it is likely that differences in
plasmaDNA reﬂect acute rather than chronic processes. Higher levels of
plasma DNA were noted in patients requiring an operation within
28 days although not necessarily at ﬁrst admission, in patients requiring
readmission after discharge, requiring admission to ICU and in those
patients likely to die. Similar prognostic potential has been noted in
patients with trauma, stroke and acute coronary syndrome [28–32]. It
may initially be surprising that patients requiring readmission have
higher levels than patients with SIRS. However the case mix of patients
requiring readmission includes some patients with organ inﬂammation
e.g., acute cholecystitis, and cancer whomay have initially been treated
conservatively, discharged and later readmitted either as emergencies or
for elective procedures.
Others have shown that plasma DNA could predict mortality and
sepsis in patients admitted to ICU [39,40], and we have also previously
shown that early elevation of plasma DNA concentrations in patients
with severe trauma predicts likely admission to ICU and mortality
[28,29]. Also plasma DNA concentrations have been shown to be
elevated in patients with cancer [23–26]. However few studies have
looked at plasma DNA concentrations as potential screening or risk-
stratiﬁcation markers in patients with undifferentiated presentation
such as the acute abdomen.
In the present format, the whole procedure of plasma DNA
quantiﬁcation, starting from blood collection, takes approximately
120 min. Technological advancement in the development of rapid
DNA analysis now makes a bed-side test possible within 10 to 15 min
of sampling [41].
The strengths of this study lie in its large sample size, and its
consecutive and complete set of data. The heterogeneity of the
diagnostic groups may be regarded as a strength or weakness
depending on the reader's perspective. Undifferentiated abdominal
pain is a common presentation which requires risk assessment and
diagnosis. In this sense the study is very practical. The limitations of
the study include the fact that it is a single centre study, the non-
speciﬁc nature of β-globin DNA which may be derived from any
nucleated cell in the body, the absence of other common markers of
severity against which plasma DNA may be compared, and the
relatively small number of cases with a positive primary outcome i.e.
ICU admission and mortality. These may limit the generalizability of
our results, and as such our study should be regarded as preliminary.
Further studies are required to validate the optimal plasma DNA
cut-off levels for diagnosis and prognosis, and to conﬁrm the
generalizability of the results. A combination of inﬂammatory and
tissue speciﬁc nucleic acid markers may aid more precise diagnosis
and risk-stratiﬁcation. In conclusion, this study shows that plasma
DNA concentrations are elevated in patients presenting with acute
abdominal pain, especially in those with cancer and organ inﬂamma-
tion, and predicts need for ICU admission and mortality.
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